RYR vs. no intervention/placebo
| | | | |
Zhibituo vs. no intervention
|
1 [22]
|
62
|
0.21 (0.04 to 0.38)
|
0.02
|
RYR supplement vs. placebo
|
1 [7]
|
83
|
0.10 (-0.04 to 0.24)
|
0.16
|
Xuezhikang vs. placebo
|
4 [8, 24–26]
|
323
|
0.11 (0.05 to 0.17)
|
0.0008
|
Zhibituo vs. placebo
|
3 [27–29]
|
291
|
0.21 (0.15 to 0.27)
|
< 0.00001
|
RYR vs. statins
| | | | |
Xuezhikang vs. simvastatin
|
14 [6, 30–34, 36–43]
|
1277
|
0.06 (-0.11 to 0.22)*
|
0.49
|
Xuezhikang vs. pravastatin
|
7 [44–50]
|
587
|
-0.01 (-0.06 to 0.03)
|
0.51
|
Xuezhikang vs. lovastatin
|
3 [51–53]
|
152
|
0.06 (0.00 to 0.11)
|
0.05
|
Xuezhikang vs. atorvastatin
|
1 [54]
|
60
|
0.01 (-0.17 to 0.19)
|
0.91
|
Xuezhikang vs. fluvastatin
|
1 [55]
|
118
|
-0.02 (-0.1 0 to 0.06)
|
0.62
|
Zhibituo vs. simvastatin
|
9 [32, 56–63]
|
666
|
-0.07 (-0.12 to -0.03)
|
0.0009
|
Zhibituo vs. provastatin
|
1 [22]
|
62
|
-0.02 (-0.22 to 0.18)
|
0.85
|
Zhibituo vs. lovastatin
|
1 [57]
|
45
|
-0.07 (-0.23 to 0.09)
|
0.39
|
RYR vs. non-statin drugs
| | | | |
Xuezhikang vs. inositol nicotinate
|
7 [65–71]
|
608
|
0.17 (0.06 to 0.28)*
|
0.002
|
Xuezhikang vs. fenofibrate
|
4 [32, 73, 74, 76]
|
257
|
0.03 (-0.06 to 0.13)
|
0.49
|
Xuezhikang vs. gemfibrozil
|
2 [77, 79]
|
108
|
-0.03 (-0.3 5 to 0.28)
|
0.83
|
Xuezhikang vs. fish oils
|
2 [80, 81]
|
70
|
0.17 (0.09 to 0.25)
|
< 0.0001
|
Xuezhikang vs. alginic sodium diester
|
1 [84]
|
60
|
0.86 (0.75 to 0.97)
|
< 0.00001
|
Xuezhikang vs. conjugated estrogens
|
1 [85]
|
44
|
0.00 (-0.09 to 0.09)
|
1.00
|
Xuezhikang vs. elastase
|
1 [86]
|
107
|
0.20 (0.10 to 0.30)
|
< 0.0001
|
Xuezhikang vs. biphenalbid
|
1 [87]
|
64
|
0.25 (0.11 to 0.39)
|
0.0003
|
Zhibituo vs. inositol nicotinate
|
6 [89–91, 93–95]
|
422
|
0.18 (0.09 to 0.27)*
|
< 0.0001
|
Zhibituo vs. fish oils
|
6 [97–102]
|
400
|
0.14 (0.06 to 0.23)*
|
0.001
|
Zhibituo vs. fenofibrate
|
2 [32, 104]
|
248
|
-0.13 (-0.37 to 0.11)
|
0.28
|
RYR vs. RYR
| | | | |
Xuezhikang vs. Zhibituo
|
7 [32, 106–111]
|
627
|
0.04 (-0.02 to 0.11)*
|
0.20
|